These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18290849

  • 1. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.
    Eur J Neurol; 2008 Mar; 15(3):284-8. PubMed ID: 18290849
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S, Cagiran I, Ormeci B, Idiman E.
    J Neurol Sci; 2004 Mar 15; 218(1-2):3-7. PubMed ID: 14759626
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.
    Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E.
    Acta Neurol Scand; 2002 Mar 15; 105(3):164-8. PubMed ID: 11886358
    [Abstract] [Full Text] [Related]

  • 7. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 15; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL, Zhang ZC, Zhang B, Jiang H, Yu CM, Zhang WJ, Yan X, Wang MX.
    Int Immunopharmacol; 2014 Dec 25; 23(2):546-9. PubMed ID: 25448497
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.
    Mult Scler Relat Disord; 2014 Nov 25; 3(6):705-11. PubMed ID: 25891549
    [Abstract] [Full Text] [Related]

  • 15. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
    Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.
    Pol Merkur Lekarski; 2005 Nov 25; 19(113):654-8. PubMed ID: 16498805
    [Abstract] [Full Text] [Related]

  • 16. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
    Brochet B, Deloire MS, Bonnet M, Salort-Campana E, Ouallet JC, Petry KG, Dousset V.
    Mult Scler; 2008 Nov 25; 14(9):1242-9. PubMed ID: 18653737
    [Abstract] [Full Text] [Related]

  • 17. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 25; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
    Ramo-Tello C, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Grau-López L.
    Mult Scler; 2016 Jan 25; 22(1):117-21. PubMed ID: 26540732
    [Abstract] [Full Text] [Related]

  • 20. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J.
    Mult Scler; 2014 May 25; 20(6):717-25. PubMed ID: 24144876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.